gemtuzumab ozogamicin


Also found in: Wikipedia.

gemtuzumab ozogamicin

 [gem-too´zoo-mab″ o″zo-gah-mi´sin]
a recombinant DNA–derived monoclonal antibody conjugated with a cytotoxic antitumor antibiotic, used as an antineoplastic in the treatment of relapsed acute myelogenous leukemia, administered intravenously.

gemtuzumab ozogamicin

/gem·tu·zu·mab ozo·ga·mi·cin/ (gem-too´zoo-mab″ o″zo-kah-mi´sin) a recombinant DNA–derived monoclonal antibody conjugated with a cytotoxic antitumor antibiotic, used as an antineoplastic.

gemtuzumab ozogamicin

[gemto̅o̅′zo̅o̅mab′ o′zo-gah-mi′sin]
a recombinant DNA-derived monoclonal antibody conjugated with a cytotoxic antitumor antibiotic used as an antineoplastic in the treatment of relapsed acute myelogenous leukemia, administered intravenously.
Mentioned in ?
References in periodicals archive ?
Health agency The Leukemia & Lymphoma Society reported on Friday the receipt of the US Food & Drug Administration approval of gemtuzumab ozogamicin (Mylotarg) for the treatment of acute myeloid leukemia, a deadly blood cancer.
Gemtuzumab ozogamicin (GO) is a cluster of difference (CD33)-specific antibody and the first immunotherapy agent that has been tested for the treatment of AML.
Pharmacokinetics of Gemtuzumab Ozogamicin, an Antibody Targeted Chemotherapy Agent for the Treatment of Patients with Acute Myeloid Leukemia in First Relapse.
Gemtuzumab ozogamicin is an engineered humanized monoclonal IgG4 antibody directed against the CD33 antigen present on leukemic cells in 80% of patients with AML.
Patients given the new type of "smart drug" called Gemtuzumab Ozogamicin (GO) as well as chemotherapy were 22% less likely to relapse and around 13% less likely to die from their disease.
3 Gemtuzumab Ozogamicin is the humanized anti CD33 antibody.
The research team studied more than 1,000 patients who received a combination of chemotherapy and the drug Gemtuzumab Ozogamicin, which is also known as Mylotarg.
He was enrolled in a treatment protocol employing three days of daunorubicin, seven days of continuous infusion cytarabine, and one dose of gemtuzumab ozogamicin (Mylotarg[R]).
The addresses of the institutions of the authors of the paper titled "Use of gemtuzumab ozogamicin in the treatment of pediatric relapsed/refractory acute myleoid leukemia" which was published in Turkish Journal of Hematology Volume:25 Issue:1 Pages 36-41 were printed wrong due to the wrong information given by the authors.
The antineoplastic agents are alemtuzumab (Campath), bevacizumab (Avastin), cetuximab (Erbitux), gemtuzumab ozogamicin (Mylotarg), ibritumomab tiuxetan (Zevalin), panitumumab (Vectibix), tositumomab and iodine 131 (Bexxar), and trastuzumab (Herceptin).
The antineoplastic agents are alemtuzumab (Campath), bevacizumab (Avastin), cetuximab (Erbitux), gemtuzumab ozogamicin (Mylotarg), ibritumomab riuxetan (Zevalin), panitumumab (Vectibix), tositu-momab and iodine 131 (Bexxar), and trastuzumab (Herceptin).
Effi cacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.